N
NeuShen Therapeutics
AAV-based gene therapy and small molecule discovery.
About NeuShen Therapeutics
NeuShen Therapeutics is a clinical-stage biotechnology company founded in 2021 that specializes in developing treatments for psychiatric and neurological disorders. The company has research and development centers in Shanghai, China, and Boston, Massachusetts. NeuShen was founded by Dr. Joan Huaqiong Shen, a physician certified by the American Board of Psychiatry and Neurology with extensive experience in global pharmaceutical R&D at companies like Eli Lilly, Wyeth, Pfizer, Janssen, and I-Mab Biopharma.
The company focuses on central nervous system (CNS) disorders, an area with significant unmet medical needs. NeuShen utilizes a dual-modality approach, combining AAV-based gene therapy with small molecule discovery to create a pipeline of drug candidates. Their business model involves B2B partnerships and licensing agreements with healthcare providers, research institutions, and pharmaceutical companies. The company's pipeline includes treatments for conditions such as depression, schizophrenia, epilepsy, Alzheimer's disease, and Parkinson's disease. One of its lead assets, NS-136, is a selective M4 muscarinic acetylcholine receptor positive allosteric modulator (M4 PAM) being developed for schizophrenia and agitation in Alzheimer's disease. This compound has advanced to Phase 2 clinical trials. Another candidate, NS-041, is a KCNQ2/3 potassium channel activator for focal onset seizures and major depressive disorder.
NeuShen has secured significant funding to advance its pipeline. In September 2022, the company closed a Pre-A financing round of approximately $20 million, led by Lapam Capital. This was followed by a Series A+ financing round in January 2026, led by Lilly Asia Ventures with participation from Pivotal bioVenture Partners and existing investors. These funds are being used to progress multiple programs through preclinical and clinical development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 80.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Core AI, Biotech and Pharma, Generative AI, Hard Tech, DT and LS, science-based
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Sep 2026 | $80M | $320M | Matrix Partners China · Legend Capital · LAV · Shanghai Guotou Pioneer | ↗ |
| SERIES A✓Equity / VC | Jan 2026 | $20M | $80M | BioVenture · Longpan Investment · SHC Shanghai Biomedical Fund · Lilly Asia Ventures | ↗ |
Growth signals
Latest recorded traffic for NeuShen Therapeutics is 2K monthly website visits, up 66.7% over the last three months. NeuShen Therapeutics's team grew 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NeuShen Therapeutics in the Jing'an District ecosystem
The NeuShen Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Lapam Capital- TCTTM Capital
Series A8 investors entered at this stage
Lilly Asia Ventures
BioVenture- LILongpan Investment
SHC Shanghai Biomedical Fund
Matrix Partners China
Legend Capital- LALAV
Shanghai Guotou Pioneer
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeuShen Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuShen Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









